Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China flag China · Delayed Price · Currency is CNY
19.89
-0.79 (-3.82%)
Nov 17, 2026, 3:00 PM CST

Nanjing Vazyme Biotech Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,5521,3731,3761,2843,5651,865
Other Revenue
4.994.992.312.413.813.78
1,5571,3781,3781,2863,5691,869
Revenue Growth
15.79%-0.00%7.15%-63.97%91.00%19.44%
Cost of Revenue
506.35457.67437.47514.891,393389.97
Gross Profit
1,050920.21940.43771.12,1761,479
Selling, General & Admin
769.48724.11722.83708.87818.98499.3
Research & Development
296.26280.67300.39338.62396.11230.32
Other Operating Expenses
28.898.319.82.4219.287.05
Operating Expenses
1,1121,0321,0531,0431,326748.74
Operating Income
-61.49-111.66-112.85-271.53850.23729.91
Interest Expense
-21.68-24.17-27.25-35.07-12.48-3.86
Interest & Investment Income
23.3222.922.7360.2465.4227.15
Currency Exchange Gain (Loss)
3.373.37-1.993.185.04-2.32
Other Non Operating Income (Expenses)
-17.91-1.08-7.52-3.91-45.03-0.88
EBT Excluding Unusual Items
-74.38-110.63-126.88-247.09863.18750
Gain (Loss) on Sale of Investments
52.5552.5955.3643.0445.95.83
Gain (Loss) on Sale of Assets
-0.68-0.29-2.15.67-0.64-2.34
Asset Writedown
-22.73-0.42-1.8-1.73-204.23-
Other Unusual Items
24.3721.0517.1684.39-94.8210.96
Pretax Income
-20.87-37.71-58.25-115.71609.39764.45
Income Tax Expense
-11.09-15.2-38.63-42.8515.8886.16
Earnings From Continuing Operations
-9.78-22.51-19.62-72.86593.51678.29
Minority Interest in Earnings
10.785.891.531.910.74-
Net Income
0.99-16.61-18.09-70.96594.25678.29
Net Income to Common
0.99-16.61-18.09-70.96594.25678.29
Net Income Growth
-----12.39%-17.46%
Shares Outstanding (Basic)
655539470512518472
Shares Outstanding (Diluted)
655539470512518472
Shares Change
79.68%14.77%-8.27%-1.18%9.95%1.96%
EPS (Basic)
0.00-0.03-0.04-0.141.151.44
EPS (Diluted)
0.00-0.03-0.04-0.141.151.44
EPS Growth
-----20.32%-19.04%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
242.09185.77-84.58-79.91-227.69354.84
Free Cash Flow Per Share
0.370.34-0.18-0.16-0.440.75
Dividend Per Share
0.3850.3850.1390.0770.9620.300
Dividend Growth
233.28%177.69%80.10%-92.00%220.50%-
Gross Margin
67.47%66.78%68.25%59.96%60.98%79.13%
Operating Margin
-3.95%-8.10%-8.19%-21.12%23.82%39.06%
Profit Margin
0.06%-1.21%-1.31%-5.52%16.65%36.30%
Free Cash Flow Margin
15.55%13.48%-6.14%-6.21%-6.38%18.99%
EBITDA
16.9-19.75-2.9-173.87913.6761.17
EBITDA Margin
1.08%-1.43%-0.21%-13.52%25.60%40.73%
D&A For EBITDA
78.3991.91109.9497.6663.3731.26
EBIT
-61.49-111.66-112.85-271.53850.23729.91
EBIT Margin
-3.95%-8.10%-8.19%-21.11%23.82%39.06%
Effective Tax Rate
----2.61%11.27%
Revenue as Reported
1,5571,3781,3781,2863,5691,869